These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 32932571)

  • 1. [Progress in research of specific antibody dynamic characteristics in patients with COVID-19].
    Zhao HT; Peng ZB; Yang XK; Li ZL; Ren MR; Qin Y; Sun XJ; Yu JX; An ZJ; Mao NY; Xu WW; Li ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jan; 42(1):39-43. PubMed ID: 32932571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological research of COVID-19 and emerging infectious diseases].
    Cao XT
    Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(1):1-6. PubMed ID: 33423443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The known unknowns of T cell immunity to COVID-19.
    Karlsson AC; Humbert M; Buggert M
    Sci Immunol; 2020 Nov; 5(53):. PubMed ID: 33208380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
    Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH
    J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.
    Figueiredo-Campos P; Blankenhaus B; Mota C; Gomes A; Serrano M; Ariotti S; Costa C; Nunes-Cabaço H; Mendes AM; Gaspar P; Pereira-Santos MC; Rodrigues F; Condeço J; Escoval MA; Santos M; Ramirez M; Melo-Cristino J; Simas JP; Vasconcelos E; Afonso Â; Veldhoen M
    Eur J Immunol; 2020 Dec; 50(12):2025-2040. PubMed ID: 33084029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients.
    Mazzoni A; Maggi L; Capone M; Spinicci M; Salvati L; Colao MG; Vanni A; Kiros ST; Mencarini J; Zammarchi L; Mantengoli E; Menicacci L; Caldini E; Romagnani S; Liotta F; Morettini A; Rossolini GM; Bartoloni A; Cosmi L; Annunziato F
    Eur J Immunol; 2020 Dec; 50(12):2013-2024. PubMed ID: 33080068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
    Jacobs JJL
    Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
    Ni L; Ye F; Cheng ML; Feng Y; Deng YQ; Zhao H; Wei P; Ge J; Gou M; Li X; Sun L; Cao T; Wang P; Zhou C; Zhang R; Liang P; Guo H; Wang X; Qin CF; Chen F; Dong C
    Immunity; 2020 Jun; 52(6):971-977.e3. PubMed ID: 32413330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.
    Siracusano G; Pastori C; Lopalco L
    Front Immunol; 2020; 11():1049. PubMed ID: 32574261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
    Maine GN; Lao KM; Krishnan SM; Afolayan-Oloye O; Fatemi S; Kumar S; VanHorn L; Hurand A; Sykes E; Sun Q
    J Clin Virol; 2020 Dec; 133():104663. PubMed ID: 33161369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
    Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
    J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus.
    Zhao J; Liao X; Wang H; Wei L; Xing M; Liu L; Zhang Z
    Clin Infect Dis; 2020 Nov; 71(16):2233-2235. PubMed ID: 32270178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
    Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
    Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
    Front Immunol; 2020; 11():1936. PubMed ID: 32849650
    [No Abstract]   [Full Text] [Related]  

  • 20. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Qu J; Wu C; Li X; Zhang G; Jiang Z; Li X; Zhu Q; Liu L
    Clin Infect Dis; 2020 Nov; 71(16):2255-2258. PubMed ID: 32337590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.